NDA 021251 · Abbvie
Kaletra
Lopinavir, Ritonavir · Oral · Cytochrome P450 3A Inhibitor; Protease Inhibitor
Accelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Sep 15, 2000
Approved uses
12
Original approval plus efficacy supplements
Registered trials
372
120 Phase 3, 10 recruiting
FAERS reports
13,489
12,415 serious, 1,781 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 2015 Supplement 49 · Efficacy LetterLabel
- Jan 28, 2015 Supplement 47 · Efficacy LetterLabel
- Apr 27, 2010 Supplement 31 · Efficacy LetterLabel
- Apr 20, 2009 Supplement 26 · Efficacy LabelLetter
- Jun 20, 2008 Supplement 22 · Efficacy · priority review Pediatric Written RequestPediatric Amendment 1Pediatric Amendment 2
- Nov 9, 2007 Supplement 18 · Efficacy · priority review LetterLabel
- Apr 20, 2007 Supplement 12 · Efficacy LabelLetter
- Oct 19, 2004 Supplement 10 · Efficacy ReviewLetterLabel
- Nov 27, 2002 Supplement 5 · Efficacy ReviewLabel
- Jan 18, 2002 Supplement 3 · Efficacy
- Jan 18, 2002 Supplement 4 · Efficacy LabelReviewLetter
- Sep 15, 2000 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination · priority review Accelerated approvalLetterLabelReview
1 products under this application
- KALETRA · LOPINAVIR 80MG/ML; RITONAVIR 20MG/ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Lopinavir" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited CountriesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01061151 · 3,747 participants · Start Mar 1, 2011 · Primary completion Sep 30, 2016
Drug: Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers and 6 more · For: HIV Infections
Sites: Pune, India; Blantyre, Malawi; Lilongwe, Malawi · 14 sites in all
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00074581 · 3,526 participants · Start Feb 2005 · Primary completion May 2015
Drug: Atazanavir; Didanosine and 8 more · For: HIV Infections
Sites: Boston, Massachusetts; Gaborone, Botswana; Nova Iguaçu, Brazil · 17 sites in all
- Breastfeeding, Antiretroviral, and Nutrition StudyPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT00164736 · 2,369 participants · Start Mar 2004 · Primary completion Jan 2010
Drug: Maternal zidovudine/lamivudine/lopinavir-ritonavir; Infant nevirapine · For: HIV Infections
Sites: Lilongwe, Malawi
- Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"Pivotal-lookingStatus unknown
CardresearchAcademic, hospital or other
NCT04403100 · 1,968 participants (planned) · Start Jun 3, 2020 · Primary completion Feb 1, 2021
Drug: Hydroxychloroquine Sulfate Tablets; Lopinavir/ Ritonavir Oral Tablet and 2 more · For: COVID-19; Coronavirus Infection; Virus Disease and 2 more
Sites: Belo Horizonte, Brazil; Betim, Brazil; Ouro Preto, Brazil · 4 sites in all
- Antiretroviral Therapy for Advanced HIV Disease in South AfricaPivotal-lookingCompleted
National Institutes of Health Clinical Center (CC)NIH
NCT00342355 · 1,771 participants · Start Jan 2004 · Primary completion Mar 2008
Drug: Zidovudine; Stavudine and 4 more · For: HIV
Sites: Centurion, South Africa; Eastaern Cape, South Africa; Free State, South Africa · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction1,338
- depression1,141
- nausea791
- drug exposure during pregnancy778
- diarrhoea774
- foetal exposure during pregnancy757
- anxiety712
- vomiting712
- off label use695
- pain692
- emotional distress578
- renal failure540
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 761 |
| 2005 | 608 |
| 2006 | 677 |
| 2007 | 725 |
| 2008 | 999 |
| 2009 | 1,056 |
| 2010 | 922 |
| 2011 | 628 |
| 2012 | 681 |
| 2013 | 469 |
| 2014 | 576 |
| 2015 | 587 |
| 2016 | 407 |
| 2017 | 268 |
| 2018 | 312 |
| 2019 | 427 |
| 2020 | 1,446 |
| 2021 | 862 |
| 2022 | 473 |
| 2023 | 217 |
| 2024 | 137 |
| 2025 | 177 |
| 2026 | 69 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kaletra (Lopinavir/Ritonavir)
2024 spending
$295K
Beneficiaries
52
262 claims
Per beneficiary
$5,668
$7.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $14,556,207 |
| 2021 | $9,065,449 |
| 2022 | $2,288,398 |
| 2023 | $497,757 |
| 2024 | $294,717 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Not Available].
Soto A, Quiñones-Laveriano DM, Garcia PJ, et al. · Rev Peru Med Exp Salud Publica 2020 · Multicenter Study, Randomized Controlled Trial
- Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
Ibrahim S, Siemieniuk RAC, Oliveros MJ, et al. · BMJ 2025 · Network Meta-Analysis, Systematic Review
- Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Musiime V, Bwakura-Dangarembizi M, Szubert AJ, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Pharmacokinetics of Dexamethasone in Tuberculous Meningitis.
Calderin JM, Resendiz-Galvan JE, Abdelgawad N, et al. · Clin Infect Dis 2026 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Reduced lopinavir exposure during pregnancy.
Stek AM, Mirochnick M, Capparelli E, et al. · AIDS 2006 · Clinical Trial, Comparative Study
- Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.
Amani B, Khanijahani A, Amani B, et al. · J Pharm Pharm Sci 2021 · Meta-Analysis, Systematic Review
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.